Emerging Oral Therapies for the Treatment of Psoriasis: A Review of Pipeline Agents.

ABSTRACT: The introduction of biologic agents for the treatment of psoriasis has revolutionized the current treatment landscape, targeting cytokines in the interleukin (IL)-23/IL-17 pathway and demonstrating strong efficacy and safety profiles in clinical trials. These agents however are costly, are associated with a risk of immunogenicity, and require administration by intravenous or subcutaneous injection, limiting their use among patients. Oral therapies, specifically small molecule and microbiome therapeutics, have the potential to be more convenient and cost-effective agents for patients and have been a focus of development in recent years, with few targeted oral medications available for the disease. In this manuscript, we review pipeline oral therapies for psoriasis identified through a searc

SUBMITTER: Drakos A 

PROVIDER: S-EPMC10819460 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature